Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Open accessThe DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Several studies have reported that cellular and soluble components of the tumor microenvironment (TME) play a key role in cancer-initiation and progression. Considering the relevance and the complexity of TME in cancer biology, recent research has focused on the investigation of the TME content, in terms of players and informational exchange. Understanding the crosstalk between tumor and non-tumor cells is crucial to design more beneficial anti-cancer therapeutic strategies. Malignant pleural mesothelioma (MPM) is a complex and heterogenous tumor mainly caused by asbestos exposure with few treatment options and low life expectancy after standard therapy. MPM leukocyte infiltration is rich in macrophages. Given the failure of macrophages to eliminate asbestos fibers, these immune cells accumulate in pleural cavity leading to the establishment of a unique inflammatory environment and to the malignant transformation of mesothelial cells. In this inflammatory landscape, stromal and immune cells play a driven role to support tumor development and progression via a bidirectional communication with tumor cells. Characterization of the MPM microenvironment (MPM-ME) may be useful to understand the complexity of mesothelioma biology, such as to identify new molecular druggable targets, with the aim to improve the outcome of the disease. In this review, we summarize the known evidence about the MPM-ME network, including its prognostic and therapeutic relevance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2 Cellular and soluble factors in MPM-ME. The interconnection between tumor cells and the surrounding stromal and immune component is necessary to create a permissive environment for cancer growth, immune escape and invasiveness [59]. Tumor cells, by the release of the growth factors FGF-2 and PDGF-AA, recruited fibroblast at tumor sites promoting their pro-tumoral activity as CAFs. In turn, these CAFs secreted the HGFs, produced ECM-related proteins, expressed the CTGF and other cytokines supporting tumor growth [65,66]. Additionally, MPM cells have been found to express the CTGF as modulator of ECM-related proteins and supporter of cancer invasiveness [62]. CAFs as well as tumor cells, via the release of the angiogenic VEGF, promoted the recruitment of endothelial cells and the vasculogenesis [67,69,70]. Exhausted Th and CD8+ T cells are also present in TME, characterized by the expression of immune checkpoint molecules, such as PD-1, TIM3, LAG3 [72]. Moreover, PD-L1 signaling induced Th cells reprogramming in Treg cells [73]. Moreover, the NK cells showed an immunosuppressive phenotype and low cytotoxicity [77]. TAMs, which represent the most abundant immune population [36], are recruited at tumor sites by tumor-produced CCL2 [92]. MPM cells enhance the malignancy of macrophages via the release of TGF-β, IL-10, exosomes (EVs) and M-CSF [36]. The presence of M-CSF and IL-34 was associated with short survival and chemoresistance [98,99]. Recently, the inhibition of CSF-1R has been shown to reduce mesothelioma progression and increase the susceptibility of MPM to immune checkpoint inhibitors [101]. The activation of the IL-1β/IL-1R signaling pathway in tumors by TAMs is correlated with the acquisition of a CSC-like phenotype [96]. As observed in other tumor types, adenosine (ADO) pathways may be involved in MM cells-TAMs interaction, inducing the release of pro-tumoral cytokines and promoting TAMs proliferation [115,127,128]. Although limited data indicate its involvement in MPM immunosuppression [117], a deep investigation is required. This figure was prepared using a template on the Servier medical art website (http://smart.servier.com/).](https://figures.cochat.ai/paper-figures/53591be3c5c7415f82a942568ac3bf92/mesothelioma-malignancy-and-the-microenvironment-molecular-mechanisms-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While under normal conditions the Adenosinergic Pathway (AP) is fine-tuned and controlled, in cancer the signaling is altered, promoting malignant cell transformation. AP in cancer cells by increasing the secretion of cytokines and immune modulatory factors, including IL6, IL10, TGFβ, and VEGF, and activating survival/signaling pathways such as PI3K-Akt-mTOR, sustains immunosuppression and”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, despite the novel and promising strategies targeting its TME, such as immunotherapy and the combination of immuno/chemotherapy, included in ongoing clinical trials on MPM, as recently reviewed in [8,26,148,149,150], the efficacy of these therapeutic approaches remains to be confirmed.”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Adhikary, G., Grun, D., Alexander, H. R., Friedberg, J. S., Xu, W., Keillor, J. W., Kandasamy, S., & Eckert, R. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26130 · Cited by 40 · cited 1×
“Inactivation of TG2 has been shown to decrease the expression of epithelialto-mesenchymal transition markers (Fibronectin, MMP-9, Slug and Snail), the Matrigel invasive abilities and increased the levels of the pro-apoptotic factors as caspase-9 and PARP activity [55].”
BackgroundRetractedRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270 · cited 1×
“Several reports have documented the importance of TME interactions to sustain tumor growth and metastasis [57].”
BackgroundInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384 · cited 1×
“Additionally, in vivo studies have demonstrated the efficacy of a recently developed monoclonal antibody anti-CSF-1R (RG7155) in the reduction of CD68+/CD163+ TAMs in mesothelioma biopsies [102].”
BackgroundTumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
The Phagocytic Function of Macrophage-Enforcing Innate Immunity and Tissue Homeostasis
Hirayama, D., Iida, T., & Nakase, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010092 · Cited by 927 · cited 1×
“Macrophages are a heterogenous population of immune cells acting by phagocytosis and destruction of foreign antigens [78].”
BackgroundBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910 · cited 1×
“Different studies have highlighted the metastatic ability of CSCs as key players of tumor progression [53], also in MM [54–56].”
BackgroundBremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691 · cited 3×
“cancer growth, immune escape and invasiveness [59].”
BackgroundHusain, Colby, Ordóñez, Allen, Attanoos, Beasley, Butnor, Chirieac, Churg, Dacic, et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0124-ra · Cited by 619 · cited 1×
“The first and most common mutation described in mesothelioma is the deletion of the Cyclin D dependent Kinase inhibitor 2A (CDKN2A) gene on chromosome 9 [9], accounting for approximately 70% of MPM cases [10].”
BackgroundIntegrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Haskó, G., Kuhel, D. G., Chen, J.-F., Schwarzschild, M. A., Deitch, E. A., Mabley, J. G., Marton, A., & Szabó, C. (2000) · The FASEB Journal · doi:10.1096/fj.99-0508com · Cited by 512
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471 · cited 1×
“These M2-like TAMs favor a pro-tumor microenvironment via the production of several growth factors and enzymes promoting angiogenesis, immunosuppression and metastases [90].”
BackgroundThe PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells
Amarnath, S., Mangus, C. W., Wang, J. C. M., Wei, F., He, A., Kapoor, V., Foley, J. E., Massey, P. R., Felizardo, T. C., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003130 · Cited by 446 · cited 2×
“Moreover, PD-L1 signaling induced Th cells reprogramming in Treg cells [73].”
BackgroundAdenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430
ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
Begicevic, R.-R., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112362 · Cited by 395 · cited 1×
“Various tumors have shown the presence of a chemoresistant sub-population of cells expressing high levels of ABC-transporters protein and increased aldehyde dehydrogenase (ALDH1) activity [46].”
BackgroundAdenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., Bueno, R., Felley‐Bosco, E., Galateau‐Salle, F., Jablons, D., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21572 · Cited by 335
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324 · cited 1×
“MPM pathogenesis has unique features because it is mainly related to the exposure of external carcinogens that are mostly represented by asbestos fibers [3,4].”
BackgroundCekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Németh, Z. H., Lutz, C. S., Csóka, B., Deitch, E. A., Leibovich, S. J., Gause, W. C., Tone, M., Pacher, P., Vizi, E. S., & Haskó, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8260 · Cited by 291
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy
Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280 · cited 1×
“Macrophages are plastic cells that, in response to environmental signals, may acquire different phenotypes [87].”
BackgroundSelf-citationPinhal-Enfield, G., Ramanathan, M., Hasko, G., Vogel, S. N., Salzman, A. L., Boons, G.-J., & Leibovich, S. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63698-x · Cited by 278
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
Shapiro, I. M., Kolev, V. N., Vidal, C. M., Kadariya, Y., Ring, J. E., Wright, Q., Weaver, D. T., Menges, C., Padval, M., McClatchey, A. I., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008639 · Cited by 249 · cited 2×
“Recent studies demonstrated a link between the presence of NF2-negative cell populations and high sensitivity to FAK-signaling inhibitors in MM cells [51].”
BackgroundCancer stem cells – important players in tumor therapy resistance
Colak, S., & Medema, J. P. (2014) · The FEBS Journal · doi:10.1111/febs.13023 · Cited by 248 · cited 1×
“MM, as with other tumor types, is strongly characterized by inter and intra-tumor heterogeneity and the persistence of resistant CSCs in tumor tissue represent the main cause of treatment failure in cancer therapy [42,43].”
BackgroundMolecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma
Carbone, M., & Yang, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2259 · Cited by 229
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224 · cited 3×
“express the CTGF as modulator of ECM-related proteins and supporter of cancer invasiveness [62].”
BackgroundInfluentialRegulation of Macrophage Function by Adenosine
Haskó, G., & Pacher, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226852 · Cited by 223
Cancer stem cells: A brief review of the current status
Kuşoğlu, A., & Biray Avcı, Ç. (2019) · Gene · doi:10.1016/j.gene.2018.09.052 · Cited by 221 · cited 1×
“CSCs theory is based on a hierarchical organization of cells in the tumor, where only a sub-set of cells with high tumor-forming properties can give rise to a heterogenous cancerous cell population associated with rapid recurrence [38,39].”
BackgroundGomez-Roca, C. A., Italiano, A., Le Tourneau, C., Cassier, P. A., Toulmonde, M., D’Angelo, S. P., Campone, M., Weber, K. L., Loirat, D., Cannarile, M. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz163 · Cited by 213
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211
Csóka, B., Németh, Z. H., Virág, L., Gergely, P., Leibovich, S. J., Pacher, P., Sun, C.-X., Blackburn, M. R., Vizi, E. S., Deitch, E. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065870 · Cited by 204
SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells
Canino, C., Mori, F., Cambria, A., Diamantini, A., Germoni, S., Alessandrini, G., Borsellino, G., Galati, R., Battistini, L., Blandino, R., et al. (2012) · Oncogene · doi:10.1038/onc.2011.485 · Cited by 200 · cited 1×
“have demonstrated that Pemetrexed induced rapid senescence in MM cells associated with the production of cytokines and pro-inflammatory molecules as well as the involvement of STAT3 signaling, that, in turn, activate epithelial-to-mesenchymal transition (EMT) programs, via the release of invasion-promoting factors (MM…”
BackgroundBlum, Y., Meiller, C., Quetel, L., Elarouci, N., Ayadi, M., Tashtanbaeva, D., Armenoult, L., Montagne, F., Tranchant, R., Renier, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09307-6 · Cited by 198
Kreckler, L. M., Wan, T. C., Ge, Z.-D., & Auchampach, J. A. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096016 · Cited by 196
Boyles, M. S. P., Young, L., Brown, D. M., MacCalman, L., Cowie, H., Moisala, A., Smail, F., Smith, P. J. W., Proudfoot, L., Windle, A. H., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.06.012 · Cited by 182 · cited 1×
“The binding of HMGB1 to specific receptors on macrophages activates the NLRP3 inflammasome and induces the secretion of IL-1β, IL-18, IL-1α, and HMGB1 itself, establishing a chronic inflammatory loop [84].”
BackgroundThe Role of Stroma in Tumor Development
Werb, Z., & Lu, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000127 · Cited by 176 · cited 1×
“The communication with the stroma is necessary to create a permissive environment allowing cancer cells to escape immune defensive mechanisms and to metastasize [58,59].”
BackgroundImpact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
Anraku, M., Cunningham, K. S., Yun, Z., Tsao, M., Li, Z., Keshavjee, S. H., Johnston, M. R., & de Perrot, M. E. (2008) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.026 · Cited by 171
Integrins, CAFs and Mechanical Forces in the Progression of Cancer
Jang, I., & Beningo, K. (2019) · Cancers · doi:10.3390/cancers11050721 · Cited by 170
Yamada, N., Oizumi, S., Kikuchi, E., Shinagawa, N., Konishi-Sakakibara, J., Ishimine, A., Aoe, K., Gemba, K., Kishimoto, T., Torigoe, T., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0881-6 · Cited by 169 · cited 1×
“A link between high density of CD8+ immune cells and improved MPM patient outcomes has also been demonstrated [71,75,76], suggesting a potential therapeutic strategy.”
BackgroundFunctional inactivation of NF2/merlin in human mesothelioma
Thurneysen, C., Opitz, I., Kurtz, S., Weder, W., Stahel, R. A., & Felley‐Bosco, E. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.08.014 · Cited by 163 · cited 1×
“Mutation in the NF2 gene, encoding the cell growth-regulating protein Merlin, has been described in about 50% of MPM [17], and has been linked to mesothelioma progression.”
BackgroundMesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
Hegmans, J. P. J. J., Hemmes, A., Hammad, H., Boon, L., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00135305 · Cited by 162 · cited 3×
“Serum and pleural effusion from mesothelioma patients have shown high levels of angiogenic cytokines as VEGF and FGF-2 that are linked with the development of new blood vessels in tumors [67,69,70].”
BackgroundCD73 as a potential opportunity for cancer immunotherapy
Ghalamfarsa, G., Kazemi, M. H., Mohseni, S. R., Masjedi, A., Hojjat‐Farsangi, M., Azizi, G., Yousefi, M., & Jadidi‐Niaragh, F. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559829 · Cited by 158
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies
Bertino, J. R., Waud, W. R., Parker, W. B., & Lubin, M. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.7.14948 · Cited by 150 · cited 1×
“For its proximity to CDKN2A, the methylthioadenosine phosphorylase (MTAP) gene is frequently co-deleted in different cancer types, including malignant mesothelioma [11,12].”
BackgroundConnective tissue growth factor (CTGF) and cancer progression
Chu, C., Chang, C.-C., Prakash, E., & Kuo, M. (2008) · Journal of Biomedical Science · doi:10.1007/s11373-008-9264-9 · Cited by 146 · cited 1×
“CTGF expression has been found in several cancer types to be correlated with malignant features, such as angiogenesis, invasion, and metastasis [63].”
BackgroundGrosso, F., Steele, N., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leighl, N. B., Reck, M., Taylor, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.9012 · Cited by 143
Regulators of macrophage activation
Martinez, F. O. (2011) · European Journal of Immunology · doi:10.1002/eji.201141670 · Cited by 142 · cited 1×
“The classical or pro-inflammatory (M1) and the alternative or antiinflammatory (M2) profiles represent the main phenotypes of polarized macrophages [88].”
BackgroundDammeijer, F., Lievense, L. A., Kaijen-Lambers, M. E., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 142 · cited 1×
“Accordingly, in vitro and in vivo studies have demonstrated that inhibition of CSF-1R might restore the CD8+ T cell anti-tumor response [98,100].”
BackgroundHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 136
Ujiie, H., Kadota, K., Nitadori, J.-I., Aerts, J. G., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., Krug, L. M., & Adusumilli, P. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009285 · Cited by 135 · cited 1×
“A link between high density of CD8+ immune cells and improved MPM patient outcomes has also been demonstrated [71,75,76], suggesting a potential therapeutic strategy.”
BackgroundThe potential of tumor-derived exosomes for noninvasive cancer monitoring
Whiteside, T. L. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1071666 · Cited by 133
Tumor-Derived Adenosine Promotes Macrophage Proliferation in Human Hepatocellular Carcinoma
Wang, J., Wang, Y., Chu, Y., Li, Z., Yu, X., Huang, Z., Xu, J., & Zheng, L. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.021 · Cited by 133
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Zhang, M., Luo, J., Sun, Q., Harber, J., Dawson, A. G., Nakas, A., Busacca, S., Sharkey, A. J., Waller, D. A., Sheaff, M. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21798-w · Cited by 132 · cited 1×
“Collectively, these data support the idea that genomic intratumor heterogeneity shapes the MPM tumor microenvironment and modulates host immune surveillance or immune escape in MPM [22].”
BackgroundTsao, A. S., Lindwasser, O. W., Adjei, A. A., Adusumilli, P. S., Beyers, M. L., Blumenthal, G. M., Bueno, R., Burt, B. M., Carbone, M., Dahlberg, S. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2036 · Cited by 120
Guo, W., Lasky, J. L., & Wu, H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000203592.04530.06 · Cited by 120 · cited 1×
“CSCs theory is based on a hierarchical organization of cells in the tumor, where only a sub-set of cells with high tumor-forming properties can give rise to a heterogenous cancerous cell population associated with rapid recurrence [38,39].”
BackgroundMacrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk
Sarode, P., Schaefer, M. B., Grimminger, F., Seeger, W., & Savai, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00324 · Cited by 117 · cited 1×
“Moreover, targeting CCL2 in lung cancer has been shown to reduce the macrophages recruitment and the M2-polarization rate, such as with active cytotoxic T cells [93].”
BackgroundCirculating and Tumor-Infiltrating Myeloid Cells Predict Survival in Human Pleural Mesothelioma
Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., & Sugarbaker, D. J. (2011) · Cancer · doi:10.1002/cncr.26143 · Cited by 115 · cited 1×
“Therefore, an increased number of infiltrating macrophages (CD68+) with a M2-like phenotype (CD163+; CD206+; IL-4Rα+) was found in MPM and peritoneal mesothelioma [92,95].”
BackgroundWang, F., Sun, W., Zhang, J., & Fan, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9973 · Cited by 115 · cited 1×
“Furthermore, MPM is indicated as a tumor with a high tendency to angiogenesis [67] and it is well known that CAFs are pro-angiogenic factors in tumors [68].”
BackgroundMossman, B. T., Shukla, A., Heintz, N. H., Verschraegen, C. F., Thomas, A., & Hassan, R. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.12.028 · Cited by 107 · cited 1×
“Accumulation of asbestos fibers leads to aberrant activation of intracellular pathways and transcriptional processes responsible for the malignant transformation of mesothelial cells and the development of a unique inflammatory microenvironment [31].”
BackgroundPasello, G., Zago, G., Lunardi, F., Urso, L., Kern, I., Vlacic, G., Grosso, F., Mencoboni, M., Ceresoli, G. L., Schiavon, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy086 · Cited by 107 · cited 4×
“Moreover, resistance to anti-cancer drugs is another feature of MPM cells, that is supported by the TME crosstalk [34].”
BackgroundInfluentialMiselis, N. R., Wu, Z. J., Van Rooijen, N., & Kane, A. B. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0579 · Cited by 106
The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma
Thapa, B., Salcedo, A., Lin, X., Walkiewicz, M., Murone, C., Ameratunga, M., Asadi, K., Deb, S., Barnett, S. A., Knight, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.013 · Cited by 106
Muller, S., Victoria Lai, W., Adusumilli, P. S., Desmeules, P., Frosina, D., Jungbluth, A., Ni, A., Eguchi, T., Travis, W. D., Ladanyi, M., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0364-z · Cited by 106
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., Hendriks, R. W., Hoogsteden, H. C., Hegmans, J. P. J. J., & Aerts, J. G. J. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605814 · Cited by 103
Wang, M., Gauthier, A. G., Daley, L.-A., Dial, K., Wu, J., Woo, J., Lin, M., Ashby, C. R., & Mantell, L. L. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7818 · Cited by 101
Lievense, L. A., Cornelissen, R., Bezemer, K., Kaijen-Lambers, M. E. H., Hegmans, J. P., & Aerts, J. G. J. V. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.021 · Cited by 99 · cited 3×
“In addition, they linked high levels of the prostanoid PGE2 in the pleural effusion from MPM patients with the increased number of M2-like macrophages, suggesting a potential role of PGE2 as promotor of a suppressive macrophage profile [61].”
BackgroundCortes‐Dericks, L., Froment, L., Boesch, R., Schmid, R. A., & Karoubi, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-304 · Cited by 98 · cited 1×
“Similarly, overexpression of ABCGE protein was found in MM cells expressing stem-like characteristics, such as a therapy resistant phenotype [44] and an elevated ALDH1 activity characterized by cells in MM with CSCs properties [47].”
BackgroundReactive Oxygen Species a Double-Edged Sword for Mesothelioma
Benedetti, S., Nuvoli, B., Catalani, S., & Galati, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4253 · Cited by 97 · cited 4×
“Moreover, HMGB1 impairs macrophage phagocytosis and induces the secretion of tumor necrosis factor-α (TNF-α), protecting the mesothelial cells from death signals and sustaining the chronic inflammatory response [81–83].”
BackgroundInfluentialCornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106742 · Cited by 91 · cited 2×
“lated with a worse prognosis and no improvement in the overall survival [36,37].”
BackgroundThe pathogenesis of mesothelioma
Carbone, M., & BEDROSSIAN, C. W. M. (2006) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.08.002 · Cited by 87 · cited 1×
“Failed phagocytosis of asbestos fibers by macrophages represents one of the possible mechanisms promoting neoplastic transformation of mesothelial cells [79].”
BackgroundChéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84 · cited 6×
“immune population [36], are recruited at tumor sites by tumor-produced CCL2 [92].”
BackgroundInfluentialMalignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83
Mesothelioma: recent highlights
Carbone, M., & Yang, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.04.29 · Cited by 79
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
Alcala, N., Mangiante, L., Le-Stang, N., Gustafson, C. E., Boyault, S., Damiola, F., Alcala, K., Brevet, M., Thivolet-Bejui, F., Blanc-Fournier, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.003 · Cited by 77
Distinctive clinical characteristics of malignant mesothelioma in young patients
Thomas, A., Chen, Y., Yu, T., Gill, A., & Prasad, V. K. (2015) · Oncotarget · doi:10.18632/oncotarget.4414 · Cited by 76 · cited 1×
“It is considered a disease of the elderly and generally manifests in an advanced stage after decades from environmental carcinogen exposure [1].”
BackgroundAdenosine up-regulates vascular endothelial growth factor in human macrophages
Ernens, I., Léonard, F., Vausort, M., Rolland-Turner, M., Devaux, Y., & Wagner, D. R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.023 · Cited by 75
Hillerdal, G., & Berg, J. (1985) · Cancer · doi:10.1002/1097-0142(19850501)55:9<1968::aid-cncr2820550923>3.0.co;2-9 · Cited by 74
Kandasamy, S., Adhikary, G., Rorke, E. A., Friedberg, J. S., Mickle, M. B., Alexander, H. R., & Eckert, R. L. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0914 · Cited by 74 · cited 1×
“Moreover, a recent study demonstrated that inhibition of YAP1/TAZ/TEAD signaling pathway in MSCs from peritoneal and pleural-derived mesothelioma cells reduced migration and invasiveness of these cells, such as increased pro-apoptotic markers expression and negatively affected the spheroid forming ability of these MM…”
BackgroundKirovski, G., Stevens, A. P., Czech, B., Dettmer, K., Weiß, T. S., Wild, P. J., Hartmann, A., Bosserhoff, A., Oefner, P. J., & Hellerbrand, C. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.059 · Cited by 73
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
Cioce, M., Canino, C., Goparaju, C., Yang, H., Carbone, M., & Pass, H. I. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.136 · Cited by 73 · cited 2×
“More recently, a chemoresistant phenotype of a CSF-1R+ population of mesothelioma cells, detected in primary cultures and MPM cell lines, resulted in being supported by the expression of both IL-34 and M-CSF ligands [99].”
BackgroundInhibition of FAK kinase activity preferentially targets cancer stem cells
Kolev, V. N., Tam, W. F., Wright, Q. G., McDermott, S. P., Vidal, C. M., Shapiro, I. M., Xu, Q., Wicha, M. S., Pachter, J. A., & Weaver, D. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18517 · Cited by 73 · cited 1×
“The tumorigenic role of FAK and its contribution to self-renewal and aggressiveness of CSCs in tumors has been widely reported [52].”
BackgroundHeterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma
Minnema-Luiting, J., Vroman, H., Aerts, J., & Cornelissen, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041041 · Cited by 73 · cited 4×
“Several findings have demonstrated that TME of MPM is enriched with a high number of immunosuppressive cells, among these M2-like TAMs and regulatory T cells represent the most abundant immune cells in the MM microenvironment [32,36].”
BackgroundInfluentialThe Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70 · cited 17×
“In mesothelioma microenvironments, TAMs represent the most abundant immune population, and the high prevalence of these cells has been associated with poor prognosis in mesothelioma patients [36] (Figure 2).”
BackgroundInfluentialDelaunay, T., Achard, C., Boisgerault, N., G�rard, M., Petithomme, T., Chatelain, C., Dutoit, S., Blanquart, C., Royer, P., Minvielle, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.128 · Cited by 69
Malignant pleural mesothelioma: recent developments
Sinn, K., Mosleh, B. O., & Hoda, M. A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000697 · Cited by 69
CD73, Tumor Plasticity and Immune Evasion in Solid Cancers
Yang, H., Yao, F., Davis, P. F., Tan, S. T., & Hall, S. R. R. (2021) · Cancers · doi:10.3390/cancers13020177 · Cited by 69
Li, Q., Wang, W., Yamada, T., Matsumoto, K., Sakai, K., Bando, Y., Uehara, H., Nishioka, Y., Sone, S., Iwakiri, S., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.060 · Cited by 67
Tumor‑associated macrophages in lung cancer: Friendly or evil? (Review)
Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11518 · Cited by 67
Patil, N. S., Righi, L., Koeppen, H., Zou, W., Izzo, S., Grosso, F., Libener, R., Loiacono, M., Monica, V., Buttigliero, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1968 · Cited by 64 · cited 3×
“Additionally, a lower infiltration of immune cells has been correlated with high expression of stromal-related and connective-related genes in mesothelioma tissues [33].”
BackgroundInfluentialAssessment of the Carcinogenicity of Carbon Nanotubes in the Respiratory System
Barbarino, M., & Giordano, A. (2021) · Cancers · doi:10.3390/cancers13061318 · Cited by 63 · cited 1×
“For this reason and for the increasing concerns about the carcinogenicity of new fibrous materials similar to asbestos, the incidence of mesothelioma is not expected to decrease in the coming years [5].”
BackgroundSelf-citationTumor Immune Microenvironment and Genetic Alterations in Mesothelioma
Hiltbrunner, S., Mannarino, L., Kirschner, M. B., Opitz, I., Rigutto, A., Laure, A., Lia, M., Nozza, P., Maconi, A., Marchini, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660039 · Cited by 62 · cited 3×
“Natural killer (NK) cells were also present in MPM samples; however, these cells showed an immunosuppressive profile and lower cytotoxic functions [77].”
BackgroundInfluentialInvolvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma
Blondy, T., D'Almeida, S. M., Briolay, T., Tabiasco, J., Meiller, C., Chené, A., Cellerin, L., Deshayes, S., Delneste, Y., Fonteneau, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000182 · Cited by 61 · cited 3×
“Accordingly, in vitro and in vivo studies have demonstrated that inhibition of CSF-1R might restore the CD8+ T cell anti-tumor response [98,100].”
BackgroundMenges, C. W., Kadariya, Y., Altomare, D. A., Talarchek, J. N., Neumann-Domer, E., Wu, Y., Xiao, G., Shapiro, I. M., Kolev, V. N., Pachter, J. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2062 · Cited by 60 · cited 1×
“The deficiency of the tumor suppressor gene, NEF2, in mesothelioma mouse models was correlated with an increase of CSCs in the tumor tissue [50].”
BackgroundHiraku, Y., Guo, F., Ma, N., Yamada, T., Wang, S., Kawanishi, S., & Murata, M. (2015) · Particle and Fibre Toxicology · doi:10.1186/s12989-016-0127-7 · Cited by 60
Heterogeneity in Malignant Pleural Mesothelioma
Oehl, K., Vrugt, B., Opitz, I., & Meerang, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061603 · Cited by 60 · cited 2×
“Thus, the knowledge of the TME complexity has become important in order to understand the molecular profile of the tumor and its involvement in therapy resistance [42].”
BackgroundSchmid (2010) · International Journal of Oncology · doi:10.3892/ijo_00000692 · Cited by 59 · cited 1×
“Different studies identified the presence of CSCs within malignant mesothelioma (MM) tissue as responsible for tumor heterogeneity [40], chemoresistance and relapse after therapy [41].”
BackgroundImmunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Schürch, C. M., Forster, S., Bruehl, F. K., Yang, S. H.-Y., Felley‐Bosco, E., & Hewer, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373235 · Cited by 57 · cited 1×
“Additionally, MM tissue has been shown to express high levels of the “don’t eat me” signal CD47 that help tumor cells to escape from the immune surveillance systems, including macrophage phagocytosis [86].”
BackgroundMarcq, E., Waele, J. D., Audenaerde, J. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. L. J. (2017) · Oncotarget · doi:10.18632/oncotarget.21113 · Cited by 57 · cited 2×
“Pleural effusions of MPM patients have shown a strong infiltration of activated cytotoxic and helper T cells; however, most of them are associated with T cell exhaustion markers, such as PD-1+, TIM-3, LAG-3, that negatively regulate lymphocyte activity [72].”
BackgroundCSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
Magkouta, S., Vaitsi, P. C., Pappas, A., Iliopoulou, M. P., Kosti, C., Psarra, K., & Kalomenidis, I. (2021) · Cancers · doi:10.3390/cancers13112546 · Cited by 56 · cited 2×
“mesothelioma progression and increase the susceptibility of MPM to immune checkpoint inhibitors [101].”
BackgroundComprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Lee, H.-S., Jang, H.-J., Choi, J. M., Zhang, J., de Rosen, V. L., Wheeler, T. M., Lee, J.-S., Tu, T., Jindra, P. T., Kerman, R. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98575 · Cited by 55
Milošević, V., Kopecka, J., Salaroglio, I. C., Libener, R., Napoli, F., Izzo, S., Orecchia, S., Ananthanarayanan, P., Bironzo, P., Grosso, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32419 · Cited by 54 · cited 1×
“Additionally, intrinsic mechanisms, such as increased expression of the autocrine loops Wnt/GSK3β/β-catenin/c-myc in MM CSCs support the over-activation of ABCB-5 as well as drug resistance of these cells [48].”
BackgroundPhenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes
Klampatsa, A., O’Brien, S., Thompson, J. C., Rao, A. S., Stadanlick, J. E., Martinez, M. C., Liousia, M., Cantu, E., Cengel, K. A., Moon, E. K., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638211 · Cited by 54 · cited 1×
“identified, by flow cytometry analysis on MPM patient samples, a proportion of CD8+ tumor-infiltrated lymphocytes (TIL) and tissue-resident memory (Trm) cells with hypofunction that was related not to the expression of inhibitor molecules but to the higher degree of Tregs in TME and to the expression of the Eomes tran…”
BackgroundImmune responses and immunotherapeutic interventions in malignant pleural mesothelioma
Bograd, A. J., Suzuki, K., Vertes, E., Colovos, C., Morales, E. A., Sadelain, M., & Adusumilli, P. S. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1103-6 · Cited by 52
Noordam, L., Kaijen, M. E. H., Bezemer, K., Cornelissen, R., Maat, L. A. P. W. M., Hoogsteden, H. C., Aerts, J. G. J. V., Hendriks, R. W., Hegmans, J. P. J. J., & Vroman, H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474318 · Cited by 52
Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Badhai, J., Pandey, G. K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., Grasso, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191257 · Cited by 49 · cited 1×
“It has been reported that in BNC mice, where the specific disruption of the Bap1, Nf2, Cdkn2ab tumor suppressor loci in the mesothelial lining of the thoracic cavity leads to a highly aggressive MM, an infiltration of leukocytes was found [19].”
BackgroundTargeting the epigenome in malignant pleural mesothelioma
McLoughlin, K. C., Kaufman, A. S., & Schrump, D. S. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.06 · Cited by 47
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma
Lu, Y. Y., Cheng, J. Q., Testa, J. R., & Jhanwar, S. C. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870090114 · Cited by 44
Yang, H., Hall, S. R. R., Sun, B., Zhao, L., Gao, Y., Schmid, R. A., Tan, S. T., Peng, R., & Yao, F. (2021) · Cancers · doi:10.3390/cancers13071561 · Cited by 44 · cited 2×
“In addition, MPM tumors harboring LATS1/2 mutation is associated with high PD-L1 expression and rather than NF2-mutant MPM, display enriched Tregs signature and plasma B cell signature [18], suggesting that different tumor-infiltrating immune cell patterns exist between dysregulation of NF2 and Hippo-YAP signaling in…”
BackgroundBiomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
Yang, H., Xu, D., Schmid, R. A., & Peng, R. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920971421 · Cited by 43
Bronte, G., Incorvaia, L., Rizzo, S., Passiglia, F., Galvano, A., Rizzo, F., Rolfo, C. D., Fanale, D., Listì, A., Natoli, C., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.011 · Cited by 41
Giurisato, E., Lonardi, S., Telfer, B., Lussoso, S., Risa-Ebrí, B., Zhang, J., Russo, I., Wang, J., Santucci, A., Finegan, K. G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2416 · Cited by 41
Self-citationPreclinical Models of Malignant Mesothelioma
Testa, J. R., & Berns, A. J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00101 · Cited by 40
Characterization of side population cells in human malignant mesothelioma cell lines
Kai, K., D’Costa, S., Yoon, B., Brody, A. R., Sills, R. C., & Kim, Y. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.04.020 · Cited by 38 · cited 3×
“Kay K et al. demonstrated that cisplatin-based treatment upon MM cell lines favored the selection of a side population with increased replicative potential and high expression levels of stemness-related genes, including OCT4, NOTCH1 and BMI1 [44].”
BackgroundCharacterisation of Mesothelioma-Initiating Cells and Their Susceptibility to Anti-Cancer Agents
Pasdar, E. A., Smits, M., Stapelberg, M., Bajzíková, M., Stantic, M., Goodwin, J., Yan, B., Štursa, J., Kovářová, J., Sachaphibulkij, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119549 · Cited by 38 · cited 1×
“Different studies identified the presence of CSCs within malignant mesothelioma (MM) tissue as responsible for tumor heterogeneity [40], chemoresistance and relapse after therapy [41].”
BackgroundOhara, Y., Enomoto, A., Tsuyuki, Y., Sato, K., Iida, T., Kobayashi, H., Mizutani, Y., Miyai, Y., Hara, A., Mii, S., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7669 · Cited by 38 · cited 5×
“Activated fibroblasts exerted a pro-tumor role by the expression of CTGF and other cytokines [65].”
BackgroundInfluentialBlum, W., Pecze, L., Felley-Bosco, E., Wu, L., de Perrot, M., & Schwaller, B. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.005 · Cited by 36 · cited 2×
“Since CSCs constitute the main targets for drug resistance, a combined approach with FAK inhibitors and chemotherapeutic agents could represent a new potential cancer treatment strategy to eradicate CSCs and overcome the mechanism of chemoresistance [45,51].”
BackgroundFerrari, L., Carugno, M., Mensi, C., & Pesatori, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00445 · Cited by 36
Cameron, R. B., Kotova, S., & Wong, R. M. H. (2015) · Cancer Management and Research · doi:10.2147/cmar.s72814 · Cited by 34
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34 · cited 1×
“Phagocytic macrophages, unable to eliminate fibers, release oxidative molecules and pro-inflammatory cytokines that promote a pro-inflammatory environment and activate signaling pathways in tumor cells that help them to survive despite the asbestos-related damage [80].”
BackgroundInflammation in malignant mesothelioma - friend or foe?
Linton, A., van Zandwijk, N., Reid, G., Clarke, S. J., Cao, C. Q., & Kao, S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.02 · Cited by 32 · cited 1×
“, inflammation in mesothelioma could be considered a “friend” or a “foe”, because chronic inflammation could be established as a favorable environment for cell survival on one hand and could induce the suppression of anti-cancer response on the other hand [35].”
BackgroundBiological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages
Izzi, V. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000180 · Cited by 28 · cited 1×
“A previous study described MM cells as able to induce the M2-like polarization, the release of pro-inflammatory cytokines (TNF-α; IL-10) and the acquisition of an immunosuppressive profile [94].”
BackgroundAlay, A., Cordero, D., Hijazo‐Pechero, S., Aliagas, E., López‐Doriga, A., Marín, R., Palmero, R., Llatjós, R., Escobar, I., Ramos, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001601 · Cited by 28
Emerging therapies in malignant pleural mesothelioma
Cinausero, M., Rihawi, K., Cortiula, F., Follador, A., Fasola, G., & Ardizzoni, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102815 · Cited by 27
Tazzari, M., Brich, S., Tuccitto, A., Bozzi, F., Beretta, V., Spagnuolo, R. D., Negri, T., Stacchiotti, S., Deraco, M., Baratti, D., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/5804230 · Cited by 26
Horio, D., Minami, T., Kitai, H., Ishigaki, H., Higashiguchi, Y., Kondo, N., Hirota, S., Kitajima, K., Nakajima, Y., Koda, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14523 · Cited by 26
Autocrine and Paracrine Purinergic Signaling in the Most Lethal Types of Cancer
Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09785-8 · Cited by 25
Experimental Model of Human Malignant Mesothelioma in Athymic Mice
Colin, D., Cottet‐Dumoulin, D., Faivre, A., Germain, S., Triponez, F., & Serre‐Beinier, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071881 · Cited by 23 · cited 3×
“In addition, the presence of M2-like TAMs in MPM-ME was linked with an increased proliferation rate of tumor cells, such as decreased efficacy of chemotherapeutic drugs [92].”
BackgroundCheng, Y. Y., Yuen, M. L., Rath, E. M., Johnson, B., Zhuang, L., Yu, T.-K., Aleksova, V., Linton, A., Kao, S., Clarke, C. J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.579327 · Cited by 23
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
Klampatsa, A., & Albelda, S. Μ. (2020) · Journal of Cellular Immunology · doi:10.33696/immunology.2.042 · Cited by 22
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22 · cited 2×
“MM contains a heterogenous population of immune cells, changing among patients and histological subtypes [32,60].”
BackgroundRozitis, E., Johnson, B., Cheng, Y. Y., & Lee, K. M. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01742 · Cited by 21
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
Wadowski, B. J., Bueno, R., & Rienzo, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684025 · Cited by 19
Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1268308 · Cited by 17
Cedrés, S., Ponce-Aix, S., Iranzo, P., Callejo, A., Pardo, N., Navarro, A., Martínez‐Martí, A., Gómez-Abecia, S., Zucchiatti, A., Sansano, I., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02275-9 · Cited by 17
Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort
Chia, P. L., Russell, P. A., Asadi, K., Thapa, B., Gebski, V., Murone, C., Walkiewicz, M., Eriksson, U., Scott, A. M., & John, T. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.022 · Cited by 17 · cited 3×
“Serum and pleural effusion from mesothelioma patients have shown high levels of angiogenic cytokines as VEGF and FGF-2 that are linked with the development of new blood vessels in tumors [67,69,70].”
BackgroundP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Pezzuto, F., Lunardi, F., Vedovelli, L., Fortarezza, F., Urso, L., Grosso, F., Ceresoli, G. L., Kern, I., Vlačić, G., Faccioli, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653497 · Cited by 16 · cited 1×
“with an immune microenvironment less sensitive to immune checkpoint inhibitors [21].”
BackgroundLau, B. W., & Kane, A. B. (2010) · PubMed · Cited by 14
Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
Berneman, Z. N., Germonpré, P. R., Huizing, M. T., de Velde, A. V., Nijs, G., Stein, B., Tendeloo, V. F. V., Lion, E., Smits, E., & Anguille, S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7583 · Cited by 13
Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
Tan, Z., Chiu, M. S., Yan, C. W., Wong, Y. C., Huang, H., Man, K., & Chen, Z. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.01.009 · Cited by 12
Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma
Chia, P. L., Russell, P. A., Scott, A. M., & John, T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1244008 · Cited by 8
Oncolytic Viral Therapy for Malignant Pleural Mesothelioma
Yang, H., Xu, D., Gao, Y., Schmid, R. A., & Peng, R. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.007 · Cited by 8
Mangone, L., Storchi, C., Bisceglia, I., & Romanelli, A. (2021) · Annals of Research in Oncology · doi:10.48286/aro.2021.20 · Cited by 3 · cited 1×
“MPM pathogenesis has unique features because it is mainly related to the exposure of external carcinogens that are mostly represented by asbestos fibers [3,4].”
Background(2003) · PubMed
Cited by
Han, Y., Zhang, T., Chen, H., & Yang, X. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103821 · Cited by 45
CSF-1R in Cancer: More than a Myeloid Cell Receptor
Cersosimo, F., Lonardi, S., Ulivieri, C., Martini, P. G. V., Morrione, A., Vermi, W., Giordano, A., & Giurisato, E. (2024) · Cancers · doi:10.3390/cancers16020282 · Cited by 42
“…in the crosstalk between immune and tumor cells, as, in fact, immune and cancer cells secreted cytokines and interleukins, which supported tumor development and progression [33,35]. lacto-genic steroid enhanced CSF-1R expression at messenger RNA and protein levels mammary epithelial cells [17].”
BackgroundSelf-citationFiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
“AP in cancer cells by increasing the secretion of cytokines and immune modulatory factors, including IL6, IL10, TGFβ, and VEGF, and activating survival/signaling pathways such as PI3K-AktmTOR, sustains immunosuppression and promotes tumor progression, metastasis, and therapy resistance [26,129,130].”
BackgroundAbd‐Elmawla, M. A., Mageed, S. S. A., AL‐Noshokaty, T. M., Elballal, M. S., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Midan, H. M., Rizk, N. I., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154817 · Cited by 26
Dietz, M. V., Quintelier, K. L. A., van Kooten, J. P., de Boer, N. L., Vink, M., Brandt‐Kerkhof, A. R. M., Verhoef, C. K., Saeys, Y., Aerts, J. G. J. V., Willemsen, M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007070 · Cited by 21
Metadata
- Authors
- Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E.
- Affiliations
- University of Siena (IT)
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Giurisato, Emanuele
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-11-12
- Volume
- 13
- Issue
- 22
- Pages
- 5664
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8616064
- OpenAlex
- W3212076185
- Cited by
- 41
- References
- 156
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 5 · 2023: 11 · 2022: 9
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by)
- Funders
- Università degli Studi di Siena
- Fondazione Beretta
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- malignant pleural mesothelioma, tumor microenvironment, asbestos exposure, tumor-associated macrophages, pleural inflammation, tumor immune infiltration, prognostic factors, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.